• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.260 -0.040 (-3.08%)
Official Closing Price Updated: 4:10 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
July 14, 2025
Via ACCESS Newswire
News headline image
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
July 01, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Broad-Spectrum Antiviral Candidate for COVID and Bird Flu Preparedness
June 18, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
June 18, 2025
Via ACCESS Newswire
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report
February 19, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Program Amid Rising Global Outbreaks
June 04, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Measles Drug Development Animal Study is Imminent
June 04, 2025
Via ACCESS Newswire
News headline image
NanoViricides (NNVC) to Unveil ‘Escape-Proof’ Antiviral Platform at Major Biotech Convention
June 02, 2025
Via AB Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform at BIO International Convention
May 28, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
May 28, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Comments on FDA COVID Booster Policy, Highlights Antiviral Strategy
May 22, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
May 22, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral Program, Prepares for Multiple Phase II Trials
May 16, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
May 16, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Antiviral as Measles and MPox Resurge Globally
May 14, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
May 14, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Clears Ethics Review for Phase II Mpox Trial in DRC
May 08, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
May 08, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) to Present at D. Boral Capital Inaugural Global Conference
May 05, 2025
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances Measles Drug Development with Broad-Spectrum Antiviral NV-387
April 29, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
April 29, 2025
Via ACCESS Newswire
News headline image
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
April 14, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
March 11, 2025
Via Investor Brand Network
Topics Intellectual Property World Trade
News headline image
NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
March 11, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
March 04, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
March 04, 2025
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financials, Advances NV-387 Antiviral Trials
February 19, 2025
Via Investor Brand Network
Topics Intellectual Property Regulatory Compliance
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu
February 11, 2025
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
February 11, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Showcases NV-387’s Broad-Spectrum Antiviral Potential at MicroCap Conference
January 29, 2025
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap